When you choose a team with the right kind of therapeutic experience, you set your study up for success. For more than 20 years, we have specialized in rare and orphan disease clinical trials supporting global research across a wide variety of indications including:
Accelerating early phase research is critical to sponsors and patients. As an oncology CRO, we have invested in advantageous site and vendor relationships with process optimizations and checkpointed cohort management techniques to expedite your early-phase study. We know how to avoid bottlenecks and deliver your study on time.
At Pharm-Olam, we maintain therapeutically-aligned staff with deep expertise in Oncology. From solid tumor to liquid tumor, our oncology CRO staff have the expertise you need to go the distance.
Staff with Oncology study expertise.
Pharm-Olam has championed small pharma and biotech companies since the earliest developments in the field. Some 74% of our clients have always been small and emerging pharma and biotechs. We continue those efforts today. With Pharm-Olam, you will find an agile CRO always focused on finding trial specific solutions to accelerate your study execution. We go the distance – helping you create a healthier world.
Our Hematology experience includes liquid tumor expertise as well as numerous non-cancerous hematology diseases. From rare hematology disorders to common diseases, we have gone the distance for our patients and are ready to support your hematology drug development.
Pharm-Olam was hired by a sponsor to run a PD-1 Inhibitor Phase I oncology study in solid tumor patients. The study moved swiftly and we completed enrollment 78 days early.
Pharm-Olam was hired by a sponsor to run a PD-1 Inhibitor Phase I oncology study in solid tumor patients. The study moved swiftly and we completed enrollment 78 days early.
A Pharm-Olam case study overview of a Phase I Oncology PD-1 Inhibitor Enrolled 78 Days Early.
Read More
Cohort management is part of conducting dose-escalation studies. This article outlines the methods our teams utilize in early-phase oncology research.
Read More
A Pharm-Olam overview of a Phase II/III study for the treatment of Recurrent Glioblastoma / Anaplastic Astrocytoma.
Learn More
